Evogene Ltd.
EVGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $9 | $6 | $2 | $1 |
| % Growth | 50.9% | 236.7% | 80.1% | – |
| Cost of Goods Sold | $5 | $4 | $3 | $3 |
| Gross Profit | $3 | $1 | -$2 | -$2 |
| % Margin | 39.8% | 24.8% | -105.9% | -222.7% |
| R&D Expenses | $14 | $18 | $18 | $19 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $11 | $10 | $10 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $25 | $28 | $28 | $29 |
| Operating Income | -$22 | -$26 | -$30 | -$31 |
| % Margin | -255.4% | -467.9% | -1,774% | -3,386% |
| Other Income/Exp. Net | $4 | $0 | -$0 | $1 |
| Pre-Tax Income | -$18 | -$26 | -$30 | -$30 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$16 | -$24 | -$27 | -$28 |
| % Margin | -193.7% | -423.4% | -1,590.3% | -2,988.5% |
| EPS | -2.89 | -5.23 | -6.46 | -0.68 |
| % Growth | 44.7% | 19% | -850% | – |
| EPS Diluted | -2.89 | -5.23 | -6.46 | -0.68 |
| Weighted Avg Shares Out | 6 | 5 | 4 | 41 |
| Weighted Avg Shares Out Dil | 6 | 5 | 4 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $3 | $3 | $2 |
| EBITDA | -$15 | -$23 | -$27 | -$28 |
| % Margin | -180.7% | -411.4% | -1,607.9% | -2,988.7% |